Xeris Biopharma Holdings (NASDAQ:XERS), a Chicago-based specialty pharmaceutical company focused on therapies for rare endocrine and metabolic diseases, on Monday reported net income of $11.1 million for its fourth quarter ended December 31, 2025.
The company said it had net income of 6 cents per share.
The results surpassed the average estimate of 3 cents per share from four analysts surveyed by Zacks Investment Research.
Revenue for the period totaled $85.8 million, exceeding the consensus forecast of $81.4 million from four analysts surveyed by Zacks.
For the full year 2025, Xeris reported a profit of $554,000.
Revenue reached $291.8 million, reflecting continued commercial momentum for its portfolio of approved products: Recorlev (levoketoconazole) for endogenous Cushing's syndrome, Gvoke (glucagon) injection for severe hypoglycemia in diabetes, and Ogluo (glucagon) pre-filled syringe in Europe.
The fourth-quarter performance was driven by strong prescription demand and market share gains in the U.S. for both Recorlev and Gvoke, international expansion of Ogluo, and disciplined expense management that supported profitability despite ongoing investments in commercial infrastructure and pipeline advancement.
For full-year 2026, Xeris provided revenue guidance in the range of $375 million to $390 million, implying year-over-year growth of approximately 28% to 34% at the midpoint.